Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Exposure-response model for the effect of AZD5069, a novel CXCR2 antagonist, on neutrophil count in asthma patients

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Poster
  • By: WAHLBY HAMREN, Ulrika (AstraZeneca R&D, Early Clinical Development, Mölndal, Sweden)
  • Co-author(s): Ulrika Wahlby Hamren: Quantitative Clinical Pharmacology, Early Clinical Development, AstraZeneca R&D, Gothenburg, Sweden
    Justin Wilkins: Occams, Amstelveen, Netherlands;, SGS Exprimo NV, Mechelem, Belgium
    Bengt Larsson: RIA TMU, Early Clinical Development, AstraZeneca R&D, Gothenburg, Sweden
    Marie Cullberg: Quantitative Clinical Pharmacology, Early Clinical Development, AstraZeneca R&D, Gothenburg, Sweden
  • Abstract:

    Backgrounds

    AZD5069 is a reversible oral CXCR2 antagonist that blocks neutrophil migration and reduces circulating neutrophil counts [1]. Models describing neutrophil dynamics after cytotoxic drug intervention have previously been published [2], however these are not applicable for the CXCR2 mechanism of action.

    Aims

    We developed a population

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses